| Acquired by | Sanofi Aventis |
| Price | $500M |
| Date | 4/09 |
| Website | biparsciences.com |
| Category | BioTech |
| Phone | (650) 635-6050 |
| Employees | |
| Founded | 2002 |
| Description | PARP Inhibitors (Cancer Therapeutics) |
| TOTAL | $68M |
| FUNDING TOTAL | $68M |
| Series A, 12/04 Vulcan Capital Quantum Technology Partners PolyTechnos Venture Partners Asset Management Company Canaan Partners | $13M |
| Series B, 2/07 Domain Associates Vulcan Capital Canaan Partners PolyTechnos Venture Partners Asset Management Company Quantum Technology Partners | $35M |
| Series C, 1/09 Vulcan Capital Canaan Partners Asset Management Company Domain Associates PolyTechnos Venture Partners Quantum Technology Partners | $20M |
| DEBT TOTAL | $5M |
| Debt, 6/06 Lighthouse Capital Partners | $5M |
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar’s key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.
BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture Partners, Asset Management Company, and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.
On April 15th, 2009, French drug maker Sanofi-Aventis S.A. announced it was acquiring BiPar Sciences for up to $500 million.
BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.
BSI-201 is in Phase 2 clinical studies of patients with triple negative breast cancer, ovarian cancer and other malignancies.
